Loading...
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
Stock
4568
4568 News & Events
-
Add to Watchlist
Trade 4568
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Forecast
Technical
Valuation
Financials
Earnings
News
4568 News
ENHERTU® Phase 3 DESTINY-Lung06 Trial Launched as First-Line Treatment for Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Oct 31 2025
Newsfilter
AstraZeneca Celebrates Significant Advances in Breast Cancer Treatments
Oct 20 2025
MarketWatch
Raludotatug Deruxtecan Shows Significant Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer in Phase 2 of REJOICE-Ovarian01 Trial
Oct 19 2025
Newsfilter
DATROWAY® Plus Rilvegostomig Demonstrates Encouraging Tumor Responses in Metastatic Urothelial Cancer Patients in TROPION-PanTumor03 Phase 2 Study
Oct 17 2025
Newsfilter
Daiichi Sankyo Opens Its Third Research Facility in San Diego
Oct 02 2025
Newsfilter
AstraZeneca Stock Soars as FDA Prepares to Evaluate Breast Cancer Treatment Drug
Oct 01 2025
MarketWatch
ENHERTU® and THP Supplemental Biologics License Application Approved in the U.S. for High-Risk HER2 Positive Early-Stage Breast Cancer Patients Before Surgery
Oct 01 2025
Newsfilter
ENHERTU® Shows Significant and Clinically Relevant Improvement in Invasive Disease-Free Survival Compared to T-DM1 in Phase 3 DESTINY-Breast05 Trial for High-Risk Early Breast Cancer Patients After Neoadjuvant Treatment
Sep 29 2025
Newsfilter
Show More News
4568 Events
No data
4568 Monitor News
No data
4568 Earnings Analysis
No Data
People Also Watch
